Cantor Fitzgerald upgraded Cartesian Therapeutics (NasdaqGM: RNAC) from Neutral to Overweight on Mar 9, 2026, with a price forecast implying 303.82% upside. The upgrade signals a sharply more bullish analyst stance that could drive meaningful RNAC-specific buying and increased volatility. Likely to affect the stock materially rather than move broader healthcare indices; monitor volume and short interest for confirmation.
Cantor Fitzgerald upgraded Cartesian Therapeutics (NasdaqGM: RNAC) from Neutral to Overweight on Mar 9, 2026, with a price forecast implying 303.82% upside. The upgrade signals a sharply more bullish analyst stance that could drive meaningful RNAC-specific buying and increased volatility. Likely to affect the stock materially rather than move broader healthcare indices; monitor volume and short interest for confirmation.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
strongly positive
Sentiment Score
0.75
Ticker Sentiment
